Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema

Shimizu, Norihiro; Oshitari, Toshiyuki; Tatsumi, Tetsuya; Takatsuna, Yoko; Arai, Miyuki; Sato, Eiju; Baba, Takayuki; Yamamoto, Shuichi

doi:10.1155/2017/1747108

Cited by 24 publications

(32 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results indicate that the BCVAs in eyes with DME and a SRD were improved more significantly than in eyes with DME without a SRD. This is consistent with our earlier short-term study [ 12 ] and also with Seo et al who reported that eyes with DME and SRD required more frequent ranibizumab injections than eyes with DME with diffuse retinal thickening [ 13 ]. In our study, however, the mean number of injections in eyes with DME and a SRD was 3.9 ± 3.0 times/year and without a SRD was 3.7 ± 2.1 times/year ( P = 0.8526; Mann–Whitney U -test).…”

Section: Discussionsupporting

confidence: 93%

“…We have recently examined real-world data on the efficacy of 6 months of IVA treatments in eyes with DME [ 12 ]. The results indicated that a lower number of IVA injections given on a practical protocol significantly improved the visual acuity in eyes with DME [ 12 ]. In this one-year study, we examine the efficacy of longer period of IVA injections in eyes with DME.…”

Section: Introductionmentioning

confidence: 99%

“…In this one-year study, we examine the efficacy of longer period of IVA injections in eyes with DME. In addition, we compare the efficacy of IVA in eyes with and without a serous retinal detachment (SRD) because the conclusions of the effect of anti-VEGF injections in eyes with or without SRD are still controversial [ 12 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Kaiho

Oshitari

Tatsumi

et al. 2017

BioMed Research International

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to determine the efficacy of one-year treatment of diabetic macular edema (DME) with intravitreal aflibercept (IVA) injections on a practical protocol. The medical records of 51 eyes of 43 patients who were diagnosed with DME and had received IVA treatments were reviewed. The best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were measured at the baseline and at 1, 3, 6, and 12 months after the IVA. The mean number of IVA injections was 3.8 ± 2.4. The mean BCVA was significantly better and the CMT was thinner after the IVA at all follow-up times (P < 0.05). The BCVA was better in eyes with a serous retinal detachment (SRD) than without a SRD (P < 0.01). There was a significant correlation between the photoreceptor outer segment (PROS) length and BCVA at the baseline and at 12 months after the IVA (P < 0.05). A fewer number of IVA injections significantly improved the BCVA and the CMT in eyes with DME after one-year treatment. IVA was more effective in the SRD+ group than in the SRD− group. The PROS length may be a predictive marker for visual outcomes after one-year treatment with IVA for DME (IRB#2272).

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Kaiho

Oshitari

Tatsumi

et al. 2017

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…This long-lasting effect is also reflected in some practical clinical reports. In their study comparing ranibizumab and aflibercept, Shimizu et al (13) concluded that visual improvement in DME patients following consecutive intravitreal injections lasted significantly longer in aflibercept group than in ranibizumab group (6 vs. 3 months).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy of Intravitreal Aflibercept and Ranibizumab in Treatment-naive Diabetic Macular Edema

Erden¹,

Çakir²,

Bölükbaşı³

et al. 2019

eamr

View full text Add to dashboard Cite

This study was conducted at the İstanbul Okmeydanı Training and Research Hospital, Clinic of Ophthalmology. The study was approved by Clinical Research Ethics Committee of Okmeydanı Training and Research Hospital and adhered to the principles of the Declaration of Helsinki. Initially, medical records and Objective: The purpose of this study was to compare the efficacy of two different intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in two treatmentnaive and statistically equal cohorts of diabetic macular edema patients. Methods: In this retrospective study, 81 eyes of 64 treatment-naive diabetic macular edema (DME) patients were enrolled. Patients were divided into two groups and both groups were treated [37 eyes with intravitreal 0.5 mg ranibizumab (IVR) and 44 eyes with intravitreal 2 mg aflibercept (IVA)] with three consecutive injections at intervals of one month. All patients underwent a detailed eye examination including optic coherence tomography and best corrected visual acuity (BCVA; Snellen), biomicroscopy, fundoscopy and applanation tonometry at preoperative, 1 st , 2 nd and 3 rd month. BCVA values were converted into logarithm of the minimum angle of resolution (logMAR) for statistical analyses. Data were evaluated with SPSS 25.0. Results: Mean BCVA (logMAR) increased from 0.58±0.28 to 0.43±0.29, 0.39±0.25 and 0.32±0.26 (p=0.001, p<0.001, p<0.001) in the IVR group and from 0.54±0.28 to 0.41±0.34, 0.43±0.39 and to 0.32±0.37 (p=0.004, p=0.023, p<0.001) in the IVA group. Mean central macular thickness (CMT) decreased from 406±82 µm to 345±65 µm (1 st month), 332±83 µm (2 nd month) and finally to 303±60 µm (3 rd month) (p<0.001) in the IVR group and from 415±88 µm to 328±79 µm, 297±54 µm and finally to 277±54 µm (p<0.001) in the IVA group, respectively. There was no significant difference between the groups in terms of BCVA (p>0.05). In the subgroup analysis, CMT gain in patients with moderate DME (CMT ≤385 µm) was found significantly better in the IVA group compared to the IVR group (1 st month: 36.9 vs. 83.6, 2 nd month: 36.2 vs. 106.3, 3 rd month: 3 nd 72.7 vs. 125.1; p<0.05). Conclusion: Both anti-VEGFs were equally effective in visual outcomes. Compared to ranibizumab, aflibercept has a rapid and superior therapeutic effect in anatomical results, especially in moderate DME cases.

show abstract

“…After the on-label use of intravitreal aflibercept injection was permitted, intravitreal aflibercept injection becomes a first choice of the medical treatment for diabetic macular edema as well as RVO in our hospital [22]. Thus, we have switched from ranibizumab to aflibercept for the treatment of CRVO in this case.…”

Section: Citation: Furuya N Oshitari T Sato E Baba T Yamamoto S (mentioning

confidence: 99%

Bilateral Central Retinal Vein Occlusion in a Patient with Mantle Cell Lymphoma

Oshitari¹

2017

OCR

Self Cite

View full text Add to dashboard Cite

Background: A Mantle Cell Lymphoma (MCL) is an aggressive B cell lymphoma and accounts for approximately 6% of all non-Hodgkin's lymphomas. A MCL has a poor prognosis with a median survival of about two to five years. We present our findings in a case of bilateral Central Retinal Vein Occlusion (CRVO) that developed in a patient with MCL. Case Presentation:A 70-year-old woman was diagnosed with primary tonsil MCL in March 2009 and progressed to complete remission after chemotherapy. In March 2014, the decimal visual acuity in her right eye decreased to 0.01 due to a CRVO. Although malignant cells were not detected in the cerebrospinal fluid, methotrexate and dexamethasone were injected intraspinally. Two weeks later, the vision in her left eye decreased to 0.03, and she was found to have a CRVO in her left eye. Hematological and systemic evaluations eliminated hypercoagulability and autoimmune disorders. Although MRI and CT showed no central nervous infiltrations, the clinical features suggested that the CRVO was related to the recurrence of the lymphoma. She was treated with an intravitreal injection of anti-VEGF (aflibercept) and panrential photocoagulation. The macula edema improved and neovascular glaucoma was prevented. Her vision did not recover because of the retinal and optic nerve ischemia. Conclusion:Bilateral CRVO can be associated with MCL although it is extremely rare. Nevertheless, clinicians should be aware of this association because a CRVO is a clinical sign of relapsing malignant ocular lymphoma.

show abstract

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema

Cited by 24 publications

References 21 publications

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Comparison of Efficacy of Intravitreal Aflibercept and Ranibizumab in Treatment-naive Diabetic Macular Edema

Bilateral Central Retinal Vein Occlusion in a Patient with Mantle Cell Lymphoma

Contact Info

Product

Resources

About